医学
克拉斯
内科学
曲妥珠单抗
表皮生长因子受体
肿瘤科
实体瘤疗效评价标准
癌症
结直肠癌
胃肠病学
临床研究阶段
毒性
乳腺癌
作者
Masataka Yagisawa,Hiroya Taniguchi,Taroh Satoh,Shigenori Kadowaki,Yu Sunakawa,Tomohiro Nishina,Yoshito Komatsu,Taito Esaki,Daisuke Sakai,Ayako Doi,Takeshi Kajiwara,Hiromi Ono,Masatoshi Asano,Nami Hirano,Justin I. Odegaard,Satoshi Fujii,Shogo Nomura,Hideaki Bando,Akihiro Sato,Takayuki Yoshino,Yoshiaki Nakamura
摘要
PURPOSE HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 ( HER2)–amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. PATIENTS AND METHODS Patients exhibited advanced solid tumors with HER2 amplification that was identified via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. RESULTS Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 amplification. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9). Confirmed overall response rate (ORR) by investigator assessment was 56.5% (95% CI, 43.3 to 69.0), thus showing a value beyond the 5% threshold. Responses were evaluated for 13 cancer types, including KRAS-mutant colorectal (1/3), PIK3CA-mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 amplification in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identified in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. CONCLUSION T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2-amplified solid tumors determined with cfDNA testing.
科研通智能强力驱动
Strongly Powered by AbleSci AI